1. Dražan Jaroš, Centar za radioterapiju,
Republic of Srpska, Bosnia and Herzegovina
2. Goran Kolarević, Republic of Srpska, Bosnia and Herzegovina
3. Milovan Savanović, Medicinski fakultet, Univerzitet Pariz-Saklej, 94276 Kremlin, Francuska, France
4. Dragoljub Mirjanić, Akademija nauka i umjetnosti Republike Srpske, Republic of Srpska, Bosnia and Herzegovina
The aim of this study was to assess the possible failure modes and analyze their consequences and effects in volumetric arc radiotherapy of prostate cancer. Failure modes and effects analysis (FMEA) is step-by-step approach for identifying all possible failures in a process. Each step of the patient pathway for volumetric arc radiotherapy of prostate cancer was defined and four major process steps were created: patient initial clinical assessment, CT simulation, treatment planning and treatment delivery. For each process step 4-16 potential failure modes and effects were identified by the multidisciplinary team responsible for the FMEA. Each potential failure mode was scored for the likelihood of occurrence, potential severity and how easily it can be detected, depending on current departmental controls. Risk priority numbers (RPNs) were calculated as the product of occurrence, severity and detectability based on Task Group (TG)-100 scale. RPNs were ranked from highest to lowest. Patient preparation and familiarization with the procedure of treatment delivery, positioning and immobilization and CT simulation and preparation had the highest RPN 216, 210 and 180, respectively. Completion of appointments and tasks for all major process steps in the oncology information system had the lowest RPN score: 8. TG-100 recommends that FMEA can be used as a tool for risk and hazard analysis. An FMEA evaluation of volumetric modulated arc therapy of prostate cancer can identify significant improvements in processes and increase in quality and safety of treatment delivery. Process steps with the highest RPNs must be addressed and new procedures must be introduced to minimize possible failures.
Ključne reči :
SIMPOZIJUM B - Biomaterijali i nanomedicina